Arizona State Retirement System Reduces Stake in Boston Scientific Corporation $BSX

Arizona State Retirement System reduced its position in Boston Scientific Corporation (NYSE:BSX) by 2.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 420,931 shares of the medical equipment provider’s stock after selling 11,163 shares during the period. Arizona State Retirement System’s holdings in Boston Scientific were worth $40,136,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of BSX. Brighton Jones LLC increased its stake in shares of Boston Scientific by 0.8% during the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after purchasing an additional 226 shares in the last quarter. FWL Investment Management LLC purchased a new position in shares of Boston Scientific during the 2nd quarter worth approximately $26,000. Main Street Financial Solutions LLC increased its stake in shares of Boston Scientific by 35.3% during the 2nd quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider’s stock worth $812,000 after purchasing an additional 1,971 shares in the last quarter. Ieq Capital LLC increased its stake in shares of Boston Scientific by 97.0% during the 2nd quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider’s stock worth $13,275,000 after purchasing an additional 60,860 shares in the last quarter. Finally, HUB Investment Partners LLC increased its stake in shares of Boston Scientific by 56.2% during the 2nd quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider’s stock worth $763,000 after purchasing an additional 2,556 shares in the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q1 results beat estimates: Boston Scientific reported $5.20B in sales (up ~11.6%) and adjusted EPS of $0.80, topping consensus and showing broad demand across key cardiovascular franchises. This underpins the bullish view on organic growth drivers. Boston Scientific announces results for first quarter 2026
• Positive Sentiment: Market reaction / reset thesis: Some analysts and outlets framed the guidance cut as a constructive “reset” that creates a buying opportunity if management executes on long-term initiatives; that framing helped shares recover after the release. Boston Scientific Just Slashed Guidance and Wall Street Followed. Is the Pullback a Buying Opportunity?
• Neutral Sentiment: Analysts cut targets but largely kept bullish ratings: Multiple firms trimmed price targets (Truist, Baird, Needham, Jefferies, Barclays) while maintaining buy/outperform calls — signaling shorter-term caution but continuing confidence in longer-term upside. Boston Scientific Analysts Slash Their Forecasts After Q1 Earnings
• Neutral Sentiment: Broker commentary called the guidance cut “prudent” with a Q2 trough expected; analysts are modeling a weaker near term but still see recovery later in 2026. That supports mixed near-term sentiment but keeps longer-term forecasts intact. Boston Scientific 2026 Guidance Cut ‘Prudent,’ Q2 Trough Expected, RBC Says
• Negative Sentiment: Guidance cut: Management trimmed FY2026 EPS and revenue guidance below Street consensus and signaled softer near-term procedure volumes in some product lines — the primary reason for the re-rating and analyst target cuts. Boston Scientific cuts 2026 profit forecast, trims revenue growth view
• Negative Sentiment: Legal risk and class-action notices: Multiple law firms have announced investigations and class-action filings alleging misstatements around procedure demand and disclosures; this raises potential litigation costs and short-to-medium-term headline risk. BOSTON SCIENTIFIC ALERT: Bragar Eagel & Squire, P.C. is Investigating Boston Scientific Corporation

Insider Transactions at Boston Scientific

In related news, CEO Michael F. Mahoney sold 160,901 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the sale, the chief executive officer directly owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. The trade was a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.34% of the company’s stock.

Boston Scientific Stock Up 1.6%

BSX opened at $65.89 on Friday. Boston Scientific Corporation has a 12 month low of $59.38 and a 12 month high of $109.50. The business has a 50-day moving average of $68.71 and a two-hundred day moving average of $86.02. The stock has a market capitalization of $97.93 billion, a price-to-earnings ratio of 27.57, a price-to-earnings-growth ratio of 1.03 and a beta of 0.78. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.68%. The firm had revenue of $5.20 billion during the quarter, compared to the consensus estimate of $5.19 billion. During the same period in the previous year, the firm earned $0.75 earnings per share. Boston Scientific’s revenue was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, research analysts expect that Boston Scientific Corporation will post 3.36 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on BSX shares. Morgan Stanley dropped their price objective on shares of Boston Scientific from $130.00 to $118.00 and set an “overweight” rating for the company in a research note on Thursday, February 5th. Weiss Ratings cut shares of Boston Scientific from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Wednesday, February 4th. Raymond James Financial reiterated an “outperform” rating and set a $88.00 price target (down from $97.00) on shares of Boston Scientific in a report on Monday, March 30th. Mizuho lowered their price target on shares of Boston Scientific from $115.00 to $90.00 and set an “outperform” rating for the company in a report on Monday, April 13th. Finally, National Bank Financial set a $115.00 price target on shares of Boston Scientific in a report on Monday, February 2nd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $93.91.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.